Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly Other Non Operating Income came in at -$87000.0 in Q1 2026, down 7.41% year-on-year from -$93960.0 in Q1 2025, and down 167.97% quarter-over-quarter from $128000.0 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$87000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 7.41% year-over-year to -$87000.0 in Q1 2026; TTM through Mar 2026 was $139000.0, a 236.27% increase from a year earlier, with the FY2024 full-year figure at -$1.9 million, down 793.43% from the prior year.
- Other Non Operating Income slipped to -$87000.0 in Q1 2026 per TARS's latest filing, from $128000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $309000.0 in Q4 2023 and bottomed at -$637000.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$7000.0 (2022), against an average of -$47400.0.
- Across the five-year window, Other Non Operating Income tumbled 3116.67% in 2024 and jumped 190.91% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at -$637000.0 in 2022, then soared by 148.51% to $309000.0 in 2023, then plunged by 85.76% to $44000.0 in 2024, then soared by 190.91% to $128000.0 in 2025, then plunged by 167.97% to -$87000.0 in 2026.
- Per Business Quant, the three latest TARS Other Non Operating Income figures stand at -$87000.0 (Q1 2026), $128000.0 (Q4 2025), and $98000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Jun 30, 2024 | -65,000.00 |
| Mar 31, 2024 | -181,000.00 |
| Dec 31, 2023 | 309,000.00 |
| Sep 30, 2023 | -36,000.00 |
| Jun 30, 2023 | 18,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | -637,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -257,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | -919,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | -39,000.00 |
| Dec 31, 2019 | -49,000.00 |
| Sep 30, 2019 | -27,000.00 |